Skip to main content
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc — Investor Relations & Filings

Ticker · PRLD ISIN · US74065P1012 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2023-05-17 Investor Presentation
Country US United States of America
Listing US PRLD

About Prelude Therapeutics Inc

https://preludetx.com/

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet needs. The company's pipeline features small molecule therapies and leverages expertise in targeted protein degradation. Key development programs include highly selective KAT6A degraders for solid tumors, such as ER+ breast cancer, and mutant-selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms. Prelude is also advancing next-generation degrader antibody conjugates (DACs) with novel payloads. The company's science-driven approach targets critical cancer cell pathways to create potentially transformative treatments.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 17, 2023, by Prelude Therapeutics Incorporated. The key content is the announcement that the company has prepared investor presentation materials, which are attached as Exhibit 99.1. The text explicitly states these materials are intended for use in investor presentations. There is no detailed financial report or earnings data included in the text itself, only a reference to the presentation materials. The document length is 3042 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, this type of document is best classified as an Investor Presentation (IP).
2023-05-17 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 8, 2023. It announces the issuance of a press release with financial results for the quarter ended March 31, 2023, and includes an investor presentation as exhibits. The text explicitly states that the press release and presentation are attached as exhibits and that the information is being furnished but not filed. The document itself does not contain detailed financial statements or substantive financial data but rather announces and furnishes these materials. The length is 4038 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results and investor presentation materials, not the full earnings release or quarterly report itself.
2023-05-08 English
ARS
Annual Report
2023-04-28 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to shareholder voting matters for an annual meeting. It includes details about voting items such as election of directors, ratification of auditors, and approval of amendments to the certificate of incorporation. The document is titled 'Definitive Additional Materials' for the proxy statement and is clearly related to soliciting shareholder votes. It is not the proxy statement itself but additional materials related to the proxy solicitation. Given the content and form type, this fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 3450 characters, which is consistent with a proxy solicitation document rather than a full annual report or other filings. Therefore, the classification is PSI with high confidence.
2023-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.